Hurel

Indi Molecular, located in Culver City, CA, specializes in the development of synthetic small molecule targeted oncology therapeutics aimed at treating ovarian cancer and KRAS G12D expressing pancreatic cancers. Utilizing a breakthrough synthetic protein chemistry platform known as Protein Catalyzed Capture (PCC), the company creates small synthetic peptide replacements for traditional antibody-based therapies. The therapeutics produced by Indi Molecular exhibit specific targeting capabilities, demonstrating picomolar to low nanomolar binding affinities and fast synthesis processes. Their innovative approach ensures stable, water-soluble molecules that retain functional activity in vivo, potentially offering significant therapeutic effects against both intracellular and extracellular targets. Generated from the website

CytRx Corporation is a biopharmaceutical company engaged in the development of high-value therapeutics utilizing its core technologies in small molecule drugs, RNAi drug discovery and DNA vaccines. RNAi has been shown to effectively silence a targeted disease-causing gene within a living cell. The technology uses ribonucleic acid to selectively turn off the harmful genes of infectious viruses or malignant tumor cells. The company s small molecule drug candidates provide cellular protection by activating molecular chaperone proteins that can repair or degrade proteins that are believed to cause many diseases. The company s research and development activities are focused on two of its technologies, FLOCOR, an intravenous agent for acute vaso-occlusive disorders and related acute care applications, and TRAXZFECT, a DNA delivery technology which may have wide applications in DNA vaccines and gene therapy. CytRx Corporation is headquartered in Los Angeles.